You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Drugs in ATC Class D10AB


✉ Email this page to a colleague

« Back to Dashboard


Drugs in ATC Class: D10AB - Preparations containing sulfur

Market Dynamics and Patent Landscape for ATC Class D10AB – Preparations Containing Sulfur

Last updated: July 28, 2025

Introduction

ATC Classification D10AB encompasses preparations containing sulfur, primarily used in dermatology and antifungal treatments. Sulfur-based preparations have a historical presence in treating skin conditions such as dandruff, seborrheic dermatitis, acne, and psoriasis. Despite the advent of advanced pharmaceuticals, sulfur remains relevant, reflecting its unique antimicrobial and keratolytic properties. The landscape of this niche combines fluctuating market demands with an evolving patent environment, shaping the competitive landscape for pharmaceutical companies, formulators, and investors.


Market Dynamics

Market Overview and Growth Drivers

The global market for sulfur-based dermatological preparations remains steady, driven by several factors:

  • Persistent Clinical Efficacy and Safety Profile: Sulfur formulations are well-established, with a longstanding safety profile making them a preferred choice for certain patient populations, including pregnant women and children [1].
  • Cost-Effectiveness: Sulfur preparations tend to be inexpensive compared to newer, targeted therapies, making them attractive in emerging markets and economically constrained regions.
  • Increasing Prevalence of Skin Disorders: Growing incidences of dandruff (affecting approximately 50% of the global population at some point), seborrheic dermatitis, and acne contribute to a stable demand [2].
  • Consumer Preference for Natural and Traditional Products: In some markets, sulfur's 'natural' reputation boosts consumer acceptance, especially in developed Western markets where plant-based or traditional medicines are gaining favor.

Market Challenges

Despite its advantages, sulfur-based products face multiple challenges:

  • Sensory and Cosmetic Limitations: Sulfur can cause odor, skin irritation, and staining of clothing, negatively impacting patient compliance.
  • Competitive Alternatives: The rise of antifungal agents like ketoconazole, terbinafine, and newer topical therapies (e.g., coal tar, zinc pyrithione) impacts sulfur's market share.
  • Regulatory Dynamics: Increased regulation around skin irritants and chemical safety prompts reformulation and limits on sulfur content in over-the-counter (OTC) products.

Regional Market Trends

  • North America and Europe: Mature markets with high acceptance but stringent regulatory environments limit aggressive growth. Adoption of combination therapies and premium formulations is evident.
  • Asia-Pacific: Fastest growth driven by large populations, increasing prevalence of skin conditions, and inclination toward traditional remedies incorporating sulfur.
  • Latin America and Africa: Emerging markets with growing OTC sales, often utilizing sulfur formulations for affordability and accessibility.

Future Outlook and Growth Opportunities

Projections indicate moderate growth in the sulfur preparations market, with Compound Annual Growth Rate (CAGR) estimated around 3-5% over the next five years [3]. Opportunities lie in reformulating sulfur products into improved, odorless, and better-tolerated formulations, along with combination therapies that enhance efficacy and patient compliance.


Patent Landscape

Historical and Current Patent Trends

The patent activities in D10AB focus on:

  • Novel Formulations: Microencapsulation of sulfur to reduce odor and irritation is a common area of innovation.
  • Combination Formulations: Patents increasingly cover combinations of sulfur with antifungal agents, corticosteroids, or keratolytics to improve efficacy and reduce side effects.
  • Delivery Systems: Innovations include gel, foam, and cream formulations optimized for skin penetration and patient adherence.

Between the late 20th and early 21st centuries, patent filings peaked during the 1980s and 1990s, aligning with the widespread commercial availability of sulfur-based treatments.

Key Patent Assignees and Innovations

Major pharmaceutical firms, along with startups, have targeted innovations around sulfur:

  • Sanofi-Aventis, Johnson & Johnson: Focused on combination products and improved delivery systems. For instance, patents on sulfur-calcium formulations aimed at reducing odor while maintaining efficacy [4].
  • Small Innovators and Biotech Firms: Engaged in microencapsulation techniques, controlled-release systems, and natural-based derivatives incorporating sulfur.

Patent Expiry and Generic Penetration

Many patents for sulfur formulations expired in the late 2000s and early 2010s, leading to increased generic proliferation. This phenomenon has intensified price competition and accessibility, but also shifted innovation towards formulations that are more consumer-friendly.

Emerging Patent Areas and Trends

Recent patent filings highlight:

  • Nanotechnology-based Delivery: nanocarriers, liposomes, and solid lipid nanoparticles to enhance solubility and reduce adverse effects.
  • Combination Therapies: dual-action compounds combining sulfur with anti-inflammatory agents or natural extracts.
  • Reformulation Beyond Topicals: Odorless and fragrance-enhanced variations to increase patient compliance.

The landscape remains dynamic, with patent filings concentrated in jurisdictions such as the U.S., Europe, and increasingly in China, reflecting strategic geographic interests.


Competitive Landscape

The sulfur preparations market is characterized by:

  • Generic Manufacturers: Widespread availability, low-cost options.
  • Innovators: Focused on reformulations and delivery systems.
  • Private Label Brands: Targeting cost-sensitive segments with sulfur-based OTC products.

Key pharmaceutical players have adopted a hybrid approach, maintaining classic formulations while investing in R&D for improved delivery and combination products.


Regulatory Considerations

Regulatory authorities like the FDA, EMA, and others scrutinize sulfur products for safety, efficacy, and labeling transparency. The push toward standardized manufacturing practices and clear safety profiles has influenced patent strategy and product development. Notably, newer formulations claiming improved tolerability or reduced odor often require substantial clinical validation and regulatory approval pathways.


Conclusion

The market for ATC D10AB preparations remains stable, with enduring clinical relevance. While sulfur’s traditional formulations face competition from advanced antifungals and biologics, innovative patent filings highlighting novel delivery systems and formulations suggest that sulfur-based treatments continue to evolve. Strategic patenting, particularly in emerging technologies such as nanotechnology and combination therapies, will shape the future landscape, balancing generic competition with innovation-driven differentiation.


Key Takeaways

  • The sulfur-based dermatological product market maintains steady demand due to efficacy, safety, and cost advantages, especially in emerging markets.
  • Challenges include sensory issues and competition from newer antifungals and biologics, prompting innovation focused on reformulation.
  • Patent activity has shifted toward delivery systems, combination therapies, and natural formulations, with a decline in basic patent filings due to patent expirations.
  • Companies investing in nanotechnology and reformulated sulfur products aim to improve patient compliance and extend market appeal.
  • Regulatory environments influence patent strategies, emphasizing safety, efficacy, and labeling clarity.

FAQs

1. Why is sulfur still relevant in dermatological treatments despite newer therapies?
Sulfur offers a well-established, cost-effective, and safe option for treating common skin conditions. Its keratolytic and antimicrobial properties remain effective, especially where affordability and traditional use are prioritized.

2. How are companies innovating within the sulfur preparation market?
Innovation focuses on microencapsulation to reduce odor and irritation, combining sulfur with other active agents, and deploying advanced delivery systems such as liposomes and nanoparticles to improve therapeutic outcomes.

3. What regions show the most promising growth for sulfur-based dermatological products?
Asia-Pacific leads in growth due to large populations and traditional medicine practices. Latin America and Africa also demonstrate increasing demand for affordable OTC sulfur formulations.

4. How does patent expiration impact the market for sulfur preparations?
Patent expirations facilitate increased generic competition, lowering prices and widening access. However, they also incentivize innovators to seek new formulations and combinations to differentiate their products.

5. What regulatory trends influence the future of sulfur-based formulations?
Regulations increasingly emphasize product safety, odor control, and patient compliance. Innovations claiming improved tolerability must meet rigorous approval standards, shaping the R&D and patenting strategies.


References

  1. Global Skin Dermatology Market Report, 2022.
  2. World Dandruff and Seborrheic Dermatitis Market, 2021.
  3. Market Watch: Dermatological Preparations Forecast, 2022-2027.
  4. Patent filings related to sulfur formulations, USPTO, Espacenet.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.